Evidence Suggests Likely Approval of Cabozantinib for Metastatic Medullary Thyroid Cancer
Long Ideas - Exelixis (NASDAQ:EXEL) has a Prescription Drug User Fee Act (PDUFA) action date on November 29th, 2012 for cabozantinib as a treatment for patients with progressive, unresectable, … Continue Reading
Read now